The proposed bill, if enacted, would introduce new provisions to the Arizona Revised Statutes regarding the appropriation of funds for research on midomafetamine as a treatment for post-traumatic stress disorder (PTSD). Specifically, it would appropriate $10 million from the state general fund for fiscal year 2025-2026 to the Department of Health Services (DHS) for awarding grants related to clinical trials or research on midomafetamine. The bill stipulates that grants can only be awarded to entities that have completed at least one late-stage clinical trial and are currently involved in the FDA drug review process for midomafetamine.

Additionally, the bill includes a provision that exempts the appropriation from lapsing, ensuring that the allocated funds remain available for their intended purpose without being subject to the usual lapsing provisions outlined in current law. Overall, these changes aim to facilitate research into midomafetamine's potential as a treatment for PTSD while ensuring that only qualified entities receive funding.